Technology
Health
Biotechnology

Sesen Bio

$1.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-3.82%) Today
$0.00 (0.00%) As of 5:52 PM EDT after-hours

Why Robinhood?

You can buy or sell Sesen Bio and other stocks, options, ETFs, and crypto commission-free!

About SESN

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. Read More The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
101.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.95M
High Today
$1.35
Low Today
$1.26
Open Price
$1.32
Volume
823.19K
52 Week High
$2.60
52 Week Low
$0.6609

Collections

Technology
Health
Biotechnology
Engineering
Therapy
Medical
Cancer Prevention
2014 IPO

SESN News

Seeking AlphaJun 19

Sesen Bio down 29% premarket on pricing equity offering

2,683

SESN Earnings

-$0.18
-$0.15
-$0.11
-$0.08
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 14, Pre-Market

Popular Stocks

More SESN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.